Home / Cannabinoids / Novel Cannabinoids
Inspired by the compounds found in cannabis, our team members have developed hundreds of novel molecules which work at the same receptor sites, in some cases with 1000x the potency. Ongoing research has shown these may have applications in next level pain relief for phantom pain, cancer related pain, treating certain forms of tumour and opiate withdrawal. These are not identical to the ‘phyto-‘ (plant) compounds, and may be even more effective in some cases.
Our drug discovery methods involve years of trial and error with synthetic cannabinoids for theraepeutic applications producing a data set which is then provided to an AI along with what is known of the receptor site. From the AI predictions, new molecules are synthesized. We have access to a proprietary drug screening system to then be screened against banks of drug targets. Some compounds from our library have been found in indicative study projects to exhibit superior pain relief qualities to analgesics currently on the market with preferable side effect profiles. Others have been shown to possess activity against certain tumours. Some were found to ameliorate opiate cravings. These premliminary results have been promising and suggest we may have new novel medications for future use.
Many other areas of medicine.
All indications were that several of our proprietary molecules could be developed into analgesic medicines and should be fast tracked for potential use in opiate withdrawal for the current fentanyl crisis.
The commericalisation pathway is the standard pharmaceutical path, we have experience in navigating the Phase 1 & 2 trials, and are in process of refining and ensuring that we have the best of the best.
BioPharm’s methods of producing generic cannabinoids using organic chemistry and propretary biosynthesis methods are not limited to phytocannabinoids, and can be adapted to produce novel pharmaceutical cannabinoids also.
Psilocybin mushrooms have been used by indigenous cultures for millennia for their therapeutic and mystical benefits. Western cultures have been denied this natural gift due to fear and taboo. Now, science has rediscovered its potential, and modern man is gaining access to this ancient tool.
Research is showing microdosing LSD (taking tiny amounts) to have powerful benefits, but the potential for overdose makes it unlikely to be allowed for public use. BioPharm have developed similar products with a ceiling level of effect to prevent overdose.
Ketamine is a popular surgical anaesthetic found to have mental health benefits, such as relief of treatment resistant depression, but is toxic to bladder. BioPharm team have worked on a number of improvements to this molecule.
MDMA is fast becoming a popular medicine for a variety of symptoms, but is toxic to heart and brain. BioPharm's EASE project has safer alternatives under development.
Stimulants such as cocaine and methamphetamine are widely used in the community but can have devastating consequences. Developing substitution drugs with less risk is becoming an attractive policy solution and we are working on the technology to get there.